- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Cell Biology
Volume 2013 (2013), Article ID 975832, 8 pages
From Prion Diseases to Prion-Like Propagation Mechanisms of Neurodegenerative Diseases
1Université Montpellier 2, 34095 Montpellier, France
2Inserm, U710, 34095 Montpellier, France
3EPHE, 75007 Paris, France
Received 17 May 2013; Revised 5 September 2013; Accepted 5 September 2013
Academic Editor: Roberto Chiesa
Copyright © 2013 Isabelle Acquatella Tran Van Ba et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. B. Prusiner, “Novel proteinaceous infectious particles cause scrapie,” Science, vol. 216, no. 4542, pp. 136–144, 1982.
- D. Dormont, “Prion diseases: pathogenesis and public health concerns,” FEBS Letters, vol. 529, no. 1, pp. 17–21, 2002.
- R. G. Will, J. W. Ironside, M. Zeidler et al., “A new variant of Creutzfeldt-Jakob disease in the UK,” The Lancet, vol. 347, no. 9006, pp. 921–925, 1996.
- A. H. Peden, M. W. Head, D. L. Ritchie, P. J. E. Bell, and P. J. W. Ironside, “Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient,” The Lancet, vol. 364, no. 9433, pp. 527–529, 2004.
- B. Sibbald, “UK patient first to contract vCJD via blood transfusion,” Canadian Medical Association Journal, vol. 170, no. 7, p. 1087, 2004.
- S. J. Wroe, S. Pal, D. Siddique et al., “Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report,” The Lancet, vol. 368, no. 9552, pp. 2061–2067, 2006.
- D. C. Gajdusek and C. J. Gibbs Jr., “Slow, latent and temperate virus infections of the central nervous system,” Research Publications—Association for Research in Nervous and Mental Disease, vol. 44, pp. 254–280, 1968.
- R. H. Kimberlin, “Scrapie agent: prions or virinos?” Nature, vol. 297, no. 5862, pp. 107–108, 1982.
- I. H. Pattison and K. M. Jones, “The possible nature of the transmissible agent of scrapie,” Veterinary Record, vol. 80, no. 1, pp. 2–9, 1967.
- T. Alper, W. A. Cramp, D. A. Haig, and M. C. Clarke, “Does the agent of scrapie replicate without nucleic acid?” Nature, vol. 214, no. 5090, pp. 764–766, 1967.
- J. S. Griffith, “Self-replication and scrapie,” Nature, vol. 215, no. 5105, pp. 1043–1044, 1967.
- S. B. Prusiner, M. P. McKinley, D. F. Groth, et al., “Scrapie agent contains a hydrophobic protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 11, pp. 6675–6679, 1981.
- S. B. Prusiner, “Prions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 23, pp. 13363–13383, 1998.
- R. Riek, S. Hornemann, G. Wider, M. Billeter, R. Glockshuber, and K. Wuthrich, “NMR structure of the mouse prion protein domain PrP(121-231),” Nature, vol. 382, no. 6587, pp. 180–182, 1996.
- K.-M. Pan, M. Baldwin, J. Nguyen et al., “Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 23, pp. 10962–10966, 1993.
- C. Govaerts, H. Wille, S. B. Prusiner, and F. E. Cohen, “Evidence for assembly of prions with left-handed β-helices into trimers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 22, pp. 8342–8347, 2004.
- J. R. Silveira, G. J. Raymond, A. G. Hughson et al., “The most infectious prion protein particles,” Nature, vol. 437, no. 7056, pp. 257–261, 2005.
- G. P. Saborio, B. Permanne, and C. Soto, “Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding,” Nature, vol. 411, no. 6839, pp. 810–813, 2001.
- I. V. Baskakov, G. Legname, S. B. Prusiner, and F. E. Cohen, “Folding of prion protein to its native alpha-helical conformation is under kinetic control,” The Journal of Biological Chemistry, vol. 276, no. 23, pp. 19687–19690, 2001.
- I. V. Baskakov, G. Legname, M. A. Baldwin, S. B. Prusiner, and F. E. Cohen, “Pathway complexity of prion protein assembly into amyloid,” The Journal of Biological Chemistry, vol. 277, no. 24, pp. 21140–21148, 2002.
- B. Février, D. Vilette, H. Laude, and G. Raposo, “Exosomes: a bubble ride for prions?” Traffic, vol. 6, no. 1, pp. 10–17, 2005.
- L. J. Vella, R. A. Sharples, V. A. Lawson, C. L. Masters, R. Cappai, and A. F. Hill, “Packaging of prions into exosomes is associated with a novel pathway of PrP processing,” Journal of Pathology, vol. 211, no. 5, pp. 582–590, 2007.
- B. Caughey and P. T. Lansbury Jr., “Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders,” Annual Review of Neuroscience, vol. 26, pp. 267–298, 2003.
- S. Simoneau, H. Rezaei, N. Salès et al., “In vitro and in vivo neurotoxicity of prion protein oligomers,” PLoS Pathogens, vol. 3, no. 8, article e125, 2007.
- J. A. Hainfeller, S. Brantner-Inthaler, L. Cervenakova et al., “The original Gerstmann-Straussler-Scheinker family of austria: divergent clinicopathological phenotypes but constant PrP genotype,” Brain Pathology, vol. 5, no. 3, pp. 201–211, 1995.
- M. H. Groschup and A. Buschmann, “Rodent models for prion diseases,” Veterinary Research, vol. 39, no. 4, article 32, 2008.
- I. H. Solomon, J. A. Schepker, and D. A. Harris, “Prion neurotoxicity: insights from prion protein mutants,” Current Issues in Molecular Biology, vol. 12, no. 2, pp. 51–61, 2010.
- H. Bueler, A. Aguzzi, A. Sailer et al., “Mice devoid of PrP are resistant to scrapie,” Cell, vol. 73, no. 7, pp. 1339–1347, 1993.
- S. B. Prusiner, D. Groth, A. Serban et al., “Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 22, pp. 10608–10612, 1993.
- G. R. Mallucci, M. D. White, M. Farmer et al., “Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice,” Neuron, vol. 53, no. 3, pp. 325–335, 2007.
- D. Westaway, S. J. DeArmond, J. Cayetano-Canlas et al., “Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins,” Cell, vol. 76, no. 1, pp. 117–129, 1994.
- C. J. Sigurdson, K. P. R. Nilsson, S. Hornemann et al., “De novo generation of a transmissible spongiform encephalopathy by mouse transgenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 1, pp. 304–309, 2009.
- J. C. Watts, K. Giles, J. Stöhr et al., “Spontaneous generation of rapidly transmissible prions in transgenic mice expressing wild-type bank vole prion protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 9, pp. 3498–3503, 2012.
- K. K. Hsiao, M. Scott, D. Foster, D. F. Groth, S. J. DeArmond, and S. B. Prusiner, “Spontaneous neurodegeneration in transgenic mice with mutant prion protein,” Science, vol. 250, no. 4987, pp. 1587–1590, 1990.
- G. C. Telling, T. Haga, M. Torchia, P. Tremblay, S. J. DeArmond, and S. B. Prusiner, “Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice,” Genes and Development, vol. 10, no. 14, pp. 1736–1750, 1996.
- R. Chiesa, P. Piccardo, B. Ghetti, and D. A. Harris, “Neurological illness in transgenic mice expressing a prion protein with an insertional mutation,” Neuron, vol. 21, no. 6, pp. 1339–1351, 1998.
- R. Chiesa, P. Piccardo, S. Dossena et al., “Bax deletion prevents neuronal loss but not neurological symptoms in a transgenic model of inherited prion disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 1, pp. 238–243, 2005.
- Y. Friedman-Levi, Z. Meiner, T. Canello et al., “Fatal prion disease in a mouse model of genetic E200K Creutzfeldt-Jakob disease,” PLoS Pathogens, vol. 7, no. 11, Article ID e1002350, 2011.
- W. S. Jackson, A. W. Borkowski, H. Faas et al., “Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice,” Neuron, vol. 63, no. 4, pp. 438–450, 2009.
- M. Fischer, T. Rulicke, A. Raeber et al., “Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie,” EMBO Journal, vol. 15, no. 6, pp. 1255–1264, 1996.
- D. W. Colby, R. Wain, I. V. Baskakov et al., “Protease-sensitive synthetic prions,” PLoS Pathogens, vol. 6, no. 1, Article ID e1000736, 2010.
- P. Gambetti, G. Puoti, and W.-Q. Zou, “Variably protease-sensitive prionopathy: a novel disease of the prion protein,” Journal of Molecular Neuroscience, vol. 45, no. 3, pp. 422–424, 2011.
- I. Mehlhorn, D. Groth, J. Stöckel et al., “High-level expression and characterization of a purified 142-residue polypeptide of the prion protein,” Biochemistry, vol. 35, no. 17, pp. 5528–5537, 1996.
- H. Zhana, J. Stöckel, I. Mehlhorn et al., “Physical studies of conformational plasticity in a recombinant prion protein,” Biochemistry, vol. 36, no. 12, pp. 3543–3553, 1997.
- G. Legname, I. V. Baskakov, H.-O. B. Nguyen et al., “Synthetic mammalian prions,” Science, vol. 305, no. 5684, pp. 673–676, 2004.
- D. W. Colby, K. Giles, G. Legname et al., “Design and construction of diverse mammalian prion strains,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 48, pp. 20417–20422, 2009.
- N. Makarava, G. G. Kovacs, O. Bocharova et al., “Recombinant prion protein induces a new transmissible prion disease in wild-type animals,” Acta Neuropathologica, vol. 119, no. 2, pp. 177–187, 2010.
- N. Makarava, G. G. Kovacs, R. Savtchenko et al., “Genesis of mammalian prions: from non-infectious amyloid fibrils to a transmissible prion disease,” PLoS Pathogens, vol. 7, no. 12, Article ID e1002419, 2011.
- N. Makarava, G. G. Kovacs, R. Savtchenko et al., “A new mechanism for transmissible prion diseases,” Journal of Neuroscience, vol. 32, no. 21, pp. 7345–7355, 2012.
- F. Wang, X. Wang, C.-G. Yuan, and J. Ma, “Generating a prion with bacterially expressed recombinant prion protein,” Science, vol. 327, no. 5969, pp. 1132–1135, 2010.
- N. R. Deleault, J. R. Piro, D. J. Walsh et al., “Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in the absence of nucleic acids,” Proceedings of the National Academy of Sciences of the United States of America, no. 22, pp. 8546–8551, 2012.
- N. R. Deleault, D. J. Walsh, J. R. Piro et al., “Cofactor molecules maintain infectious conformation and restrict strain properties in purified prions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 28, pp. E1938–E1946, 2012.
- H. F. Baker, R. M. Ridley, L. W. Duchen, T. J. Crow, and C. J. Bruton, “Induction of β(A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate—comparison with transmission of spongiform encephalopathy,” Molecular Neurobiology, vol. 8, no. 1, pp. 25–39, 1994.
- M. D. Kane, W. J. Lipinski, M. J. Callahan et al., “Evidence for seeding of β-amyloid by intracerebral infusion of Alzheimer brain extracts in β-amyloid precursor protein-transgenic mice,” Journal of Neuroscience, vol. 20, no. 10, pp. 3606–3611, 2000.
- L. C. Walker, F. Bian, M. J. Callahan, W. J. Lipinski, R. A. Durham, and H. LeVine, “Modeling Alzheimer's disease and other proteopathies in vivo: is seeding the key?” Amino Acids, vol. 23, no. 1–3, pp. 87–93, 2002.
- M. Meyer-Luehmann, J. Coomaraswamy, T. Bolmont et al., “Exogenous induction of cerebral β-amyloidogenesis is governed bf agent and host,” Science, vol. 313, no. 5794, pp. 1781–1784, 2006.
- Y. S. Eisele, U. Obermüller, G. Heilbronner et al., “Peripherally applied Aβ-containing inoculates induce cerebral β-amyloidosis,” Science, vol. 330, no. 6006, pp. 980–982, 2010.
- R. Morales, C. Duran-Aniotz, J. Castilla, L. D. Estrada, and C. Soto, “De novo induction of amyloid-β deposition in vivo,” Molecular Psychiatry, vol. 17, no. 12, pp. 1347–1353, 2011.
- F. Clavaguera, T. Bolmont, R. A. Crowther et al., “Transmission and spreading of tauopathy in transgenic mouse brain,” Nature Cell Biology, vol. 11, no. 7, pp. 909–913, 2009.
- A. de Calignon, M. Polydoro, M. Suárez-Calvet et al., “Propagation of tau pathology in a model of early Alzheimer's disease,” Neuron, vol. 73, no. 4, pp. 685–697, 2012.
- J. H. Kordower, Y. Chu, R. A. Hauser, T. B. Freeman, and C. W. Olanow, “Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease,” Nature Medicine, vol. 14, no. 5, pp. 504–506, 2008.
- J.-Y. Li, E. Englund, J. L. Holton et al., “Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation,” Nature Medicine, vol. 14, no. 5, pp. 501–503, 2008.
- K. C. Luk, V. M. Kehm, B. Zhang, P. O'Brien, J. Q. Trojanowski, and V. M. Lee, “Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice,” The Journal of Experimental Medicine, no. 5, pp. 975–986, 2012.
- K. C. Luk, V. Kehm, J. Carroll et al., “Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice,” Science, vol. 338, no. 6109, pp. 949–953, 2012.
- J. Stohr, J. C. Watts, Z. L. Mensinger et al., “Purified and synthetic Alzheimer's amyloid beta (Abeta) prions,” Proceedings of the National Academy of Sciences of the United States of America, no. 27, pp. 11025–11030, 2012.
- C. H. Hawkes, K. Del Tredici, and H. Braak, “Parkinson's disease: the dual hit theory revisited,” Annals of the New York Academy of Sciences, vol. 1170, pp. 615–622, 2009.
- H. Y. E. Chan, J. M. Warrick, I. Andriola, D. Merry, and N. M. Bonini, “Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells,” Human Molecular Genetics, vol. 11, no. 23, pp. 2905–2917, 2002.
- P.-H. Ren, J. E. Lauckner, I. Kachirskaia, J. E. Heuser, R. Melki, and R. R. Kopito, “Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates,” Nature Cell Biology, vol. 11, no. 2, pp. 219–225, 2009.